Trade Report: Today, Keryx Biopharmaceuticals Inc. (KERX) Receives Consensus Rating of “Hold” from Analysts

Today, Keryx Biopharmaceuticals Inc. (KERX) Receives Consensus Rating of “Hold” from Analysts

Shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) have been given a consensus rating of “Hold” by the fourteen research firms that are currently covering the company. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $6.24.

Several research analysts have commented on the company. FBR & Co reissued a “hold” rating on shares of Keryx Biopharmaceuticals in a research note on Saturday, November 19th. Cowen and Company restated a “neutral” rating on shares of Keryx Biopharmaceuticals in a report on Wednesday, August 3rd. Zacks Investment Research cut Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd. Stifel Nicolaus cut Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd. Finally, Brean Capital cut Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd.

A number of institutional investors have recently modified their holdings of KERX. Parametric Portfolio Associates LLC raised its position in shares of Keryx Biopharmaceuticals by 5.4% in the second quarter. Parametric Portfolio Associates LLC now owns 25,951 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 1,328 shares during the period. California State Teachers Retirement System raised its position in shares of Keryx Biopharmaceuticals by 0.9% in the third quarter. California State Teachers Retirement System now owns 167,058 shares of the biopharmaceutical company’s stock valued at $887,000 after buying an additional 1,500 shares during the period. BlackRock Group LTD raised its position in shares of Keryx Biopharmaceuticals by 5.0% in the third quarter. BlackRock Group LTD now owns 49,808 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 2,379 shares during the period. BlackRock Advisors LLC raised its position in shares of Keryx Biopharmaceuticals by 5.6% in the third quarter. BlackRock Advisors LLC now owns 45,653 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 2,413 shares during the period. Finally, Marco Investment Management LLC raised its position in shares of Keryx Biopharmaceuticals by 6.5% in the third quarter. Marco Investment Management LLC now owns 49,350 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 3,000 shares during the period. 62.15% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded up 3.32% during mid-day trading on Friday, reaching $6.23. 621,528 shares of the company’s stock traded hands. The company has a 50 day moving average of $5.19 and a 200 day moving average of $5.48. The company’s market cap is $660.13 million. Keryx Biopharmaceuticals has a 12 month low of $2.80 and a 12 month high of $7.80.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.19. The business had revenue of $6.30 million for the quarter, compared to analyst estimates of $5.53 million. Keryx Biopharmaceuticals had a negative return on equity of 270.26% and a negative net margin of 584.76%. The firm’s revenue was up 50.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.29) EPS. Analysts expect that Keryx Biopharmaceuticals will post ($1.41) earnings per share for the current fiscal year.

Related posts

Leave a Comment